Escalated dose donor lymphocyte infusion treatment in patients with primary immune deficiencies after HSCT with reduced-intensity conditioning regimen

Incremental donor lymphocyte infusion to treat mixed chimerism after allogeneic stem cell transplantation in children with non-malignant diseases

“…Our response rate of 56.2%, with more than a third of patients achieving a CR, is consistent with other reports [6,8], and confirms that a substantive proportion of patients benefits from DLI. In our cohort, responders received DLI later after HSCT than NR; this could indicate that patients with slow progression of MC were more likely to respond to DLI than those who exhibited an early drop in chimerism.…”

“…The safety profile of escalating dose DLI appeared acceptable, with low rate of aGVHD grade II-IV (12.5%) compared to others [6][7][8]. This may reflect the selection of donors and recipients: DLI was not administered in the context of HLA mismatched donors or if patients had history of significant GVHD.…”

“…Mixed chimerism (MC) post hematopoietic stem cell transplantation (HSCT) is observed in children with non-malignant diseases (NMD), especially after reduced intensity conditioning [1][2][3], and can increase the risk of graft loss (GL) and recurrence of disease [1,4,5]. Data from limited case series indicate that donor lymphocyte infusion (DLI) could revert low levels of donor chimerism to curative levels, averting the need for a second HSCT [6][7][8]. We conducted a retrospective study in 2 tertiary-care pediatric centers.…”

RETRACTED: The impact of second-donor lymphocyte infusion on secondary graft failure after allogeneic hematopoietic stem cell transplantation through activation of Foxp3 and regulatory T cells

“…MC is closely related to rejection, chronic GVHD and relapse in patients receiving allogeneic HSCT [15À17]. DLI may result in the elimination of host hematopoietic cells and the conversion of unstable MC to CC via augmentation by donor grafts [9,10]. However, few studies of the use of DLI in patients with MC and SGF have been carried out, as studies have mainly focused on thalassemia patients [12À14].…”